PALVELLA THERAPEUTICS INC (PVLA) Stock Price, Quote, News and Overview
NASDAQ:PVLA - Nasdaq - US7207952026 - Common Stock - Currency: USD
PVLA Quote, Performance and Key Statistics
PALVELLA THERAPEUTICS INC
NASDAQ:PVLA (1/23/2025, 11:09:21 AM)
13.05
-0.1 (-0.76%)
The current stock price of PVLA is 13.05 USD. In the past month the price increased by 9.58%.
PVLA Latest News, Press Releases and Analysis
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a...
PVLA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.78 | 299.85B | ||
| AMGN | AMGEN INC | 14.24 | 147.11B | ||
| GILD | GILEAD SCIENCES INC | 20.94 | 115.63B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 841.91 | 110.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.03 | 75.02B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.75B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.44B | ||
| NTRA | NATERA INC | N/A | 22.68B | ||
| BIIB | BIOGEN INC | 8.61 | 20.48B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.26B |
Related screens
About PVLA
Company Profile
Pieris Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2014-12-18. Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Company Info
PALVELLA THERAPEUTICS INC
225 Franklin Street, 26th Floor
Boston MASSACHUSETTS US
Employees: 46
Company Website: https://www.pieris.com/
Investor Relations: http://ir.pieris.com/
Phone: 18572468998
PVLA FAQ
What is the price of PVLA?
The current price of PVLA is 13.05 USD.
What is the symbol for PALVELLA THERAPEUTICS INC?
The exchange symbol of PALVELLA THERAPEUTICS INC is PVLA and it is listed on the Nasdaq exchange.
On which exchange is PVLA listed?
PVLA is listed on the Nasdaq exchange.
Is PVLA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PVLA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PVLA.
Does PVLA pay dividends?
PVLA does not pay a dividend.
What is the Price/Earnings (PE) ratio of PVLA?
PVLA does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.61).
What is the Short Interest ratio of PVLA?
The outstanding short interest for PVLA is 0.26% of its float.
PVLA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PVLA.
PVLA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PVLA. While PVLA seems to be doing ok healthwise, there are quite some concerns on its profitability.
PVLA Financial Highlights
Over the last trailing twelve months PVLA reported a non-GAAP Earnings per Share(EPS) of -12.61. The EPS increased by 54.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.74% | ||
| ROE | -98.06% | ||
| Debt/Equity | 0 |
PVLA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PVLA. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 42.86% and a revenue growth -99.92% for PVLA